tldrdaily.news logo
Tag

Crispr Therapeutics

All articles tagged with #crispr therapeutics

investment22 days ago

Top 3 Growth Stocks to Buy and Hold for Long-Term Gains

The article highlights three promising long-term growth stocks: CRISPR Therapeutics, which is pioneering gene editing with promising future medical applications; Astera Labs, a key player in AI data center interconnectivity solutions; and Alibaba, which is expanding into AI hardware and software to capitalize on China's growing AI industry. These stocks require patience but offer significant potential as they are positioned in innovative and expanding sectors.

via The Motley Fool|
#ai-technology#alibaba#crispr-therapeutics
stock-market1 year ago

"Surgery Partners Receives 'Hard Pass' in Cramer's Lightning Round"

Jim Cramer advises against investing in Surgery Partners due to the volatility of the industry, recommends buying Energy Transfer, expresses uncertainty about DigitalOcean's stock performance, discourages investing in Vodafone while suggesting Verizon instead, and acknowledges CRISPR Therapeutics' potential but cautions against its current financial situation. He also notes that MP Materials' stock has been stagnant but does not oppose it.

via CNBC|
#crispr-therapeutics#digitalocean#energy-transfer
healthcare2 years ago

"FDA Grants Dual Approval for Vertex/CRISPR Gene Therapy in Treating Inherited Blood Disorders"

The US FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy, Casgevy, for treating transfusion-dependent beta thalassemia in patients 12 years and older, making it the second US approval for the therapy. Casgevy, priced at $2.2 million, is the first treatment based on CRISPR gene editing technology to secure approval for this disorder in the United States, with an estimated peak sales of about $400 million. This therapy offers hope for patients with the severe form of the disorder, which causes life-threatening anemia requiring frequent blood transfusions.

via CNBC|
#crispr-therapeutics#gene-therapy#healthcare
healthcare2 years ago

"FDA Approves CRISPR Gene-Editing Therapy for Beta-Thalassemia and Sickle Cell Disease"

The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy, a gene editing therapy, to treat beta-thalassemia, marking the first-ever CRISPR-edited therapy for the rare genetic blood disorder. Priced at $2.2 million for the one-time ex vivo treatment, the approval is for patients 12 years and older who require regular blood transfusions to survive, and it will compete with a gene-edited therapy from startup bluebird bio.

via Endpoints News|
#beta-thalassemia#crispr-therapeutics#fda
business2 years ago

"FDA Approves CRISPR Gene Editing for Sickle Cell Treatment, Paving the Way for Breakthrough"

Shares of Crispr Therapeutics experienced volatility after the FDA approved the company's gene-editing treatment for sickle cell disease. The stock initially rallied but then fell over 8%. The treatment, developed by Crispr and co-developed by Vertex Pharmaceuticals, offers targeted and effective therapy for individuals with limited treatment options. The approval follows a previous approval by the U.K.'s regulatory agency. Crispr's stock is up nearly 50% year to date, closing at $64.54, while Vertex's stock dipped to $350.15.

via Investor's Business Daily|
#business#crispr-therapeutics#fda-approval
healthcare2 years ago

"Lyfgenia FDA Approval Sparks Competition in Sickle Cell Treatment Market"

The FDA's approval of two gene therapies for sickle cell disease paves the way for competition between Bluebird Bio's Lyfgenia and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy. While Casgevy has the advantage of being a CRISPR-based therapy, some physicians and patients may prefer the lentiviral vector technology behind Lyfgenia, despite the added risk of blood cancer.

via STAT|
#bluebird-bio#crispr-therapeutics#gene-therapy
healthcare2 years ago

"CRISPR Breakthrough: Approved Gene-Editing Treatment Poses Infertility Risk for Sickle Cell Patients"

Vertex Pharmaceuticals and CRISPR Therapeutics have received regulatory approval in the UK for their gene therapy, exa-cel, intended to treat sickle cell disease. However, new research published in Nature Medicine suggests a potential risk associated with the treatment. Patients treated with a similar gene therapy approach exhibited a higher proportion of stem cells with driver mutations associated with certain blood cancers. While the risk is not guaranteed, it raises concerns about the therapy unintentionally acting as a filter that removes healthy cells and leaves cells with dangerous mutations intact. The outcome could range from no negative consequences to additional studies being demanded by regulators or, in the worst-case scenario, the therapy being pulled from the market. Investors should be prepared for potential losses and monitor regulatory developments.

via The Motley Fool|
#crispr-therapeutics#gene-editing-therapies#healthcare
biotechnology2 years ago

CRISPR Revolutionizes CAR-T Pipeline, Expands into Autoimmune Disease Amidst Exa-cel Decision

CRISPR Therapeutics is making changes to its allogeneic CAR-T cell therapy pipeline by cutting two programs, CTX110 and CTX130, and prioritizing next-generation candidates with potential for improved clinical profiles. The company is also expanding into a new indication, autoimmune disease, while awaiting an FDA decision on its CRISPR-edited therapy exa-cel. Patients treated with CTX110 and CTX130 will be transitioned to long-term follow-up programs.

via Endpoints News|
#autoimmune-disease#biotechnology#car-t-cell-therapy
healthcare2 years ago

CRISPR Therapeutics Unveils Groundbreaking Preclinical Data at AHA Scientific Sessions 2023

CRISPR Therapeutics announced preclinical data at the American Heart Association (AHA) Scientific Sessions 2023, showcasing the potential of their investigational gene editing therapies, CTX310 and CTX320, for the treatment of cardiovascular disease. CTX310 demonstrated durable reductions in angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose, while CTX320 led to durable reductions in lipoprotein(a) (Lp(a)) levels in NHPs. Both therapies were well-tolerated. CTX310 has initiated a clinical trial targeting ANGPTL3, while CTX320 is on track to enter the clinic in the first half of 2024. The data suggest that these therapies have the potential to shift the treatment paradigm for cardiovascular disease towards a potentially one-time, durable therapy.

via Yahoo Finance|
#cardiovascular-disease#crispr-therapeutics#ctx310
finance2 years ago

October's Top Growth Stocks: No-Brainer Buys with Potential Soar

October historically tends to be a good month for stocks, and three growth stocks stand out as top buys for the final quarter of 2023: CRISPR Therapeutics, DraftKings, and Roivant Sciences. CRISPR Therapeutics is on the verge of making history with its CRISPR/Cas9 gene-edited sickle cell disease candidate, and its broad pipeline of candidates holds potential for treating various ailments. DraftKings, despite still losing money, has seen its stock soar due to its ability to grow revenue in the online gaming and sports-betting industry. Roivant Sciences, with its unique business strategy and two blockbuster immunology drugs, offers a compelling value proposition for investors.

via The Motley Fool|
#crispr-therapeutics#draftkings#finance